JP Morgan Chase’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

JP Morgan Chase’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-11,200	Closed	-$124K	–	7810
2023 Q2	$124K	Hold	11,200	–	–	﹤0.01%	5363
2023 Q1	$150K	Buy	+11,200	New	+$194K	﹤0.01%	5234
2019 Q2	–	Sell	-122,300	Closed	-$13.7M	–	6086
2019 Q1	$13.7M	Buy	+122,300	New	+$13.4M	﹤0.01%	1802
2018 Q3	–	Sell	-30,000	Closed	-$2.52M	–	5888
2018 Q2	$2.52M	Buy	+30,000	New	+$2.2M	﹤0.01%	3232
2016 Q2	–	Sell	-50,000	Closed	-$6.42M	–	5016
2016 Q1	$6.42M	Buy	+50,000	New	+$5.9M	﹤0.01%	2052
2014 Q4	–	Sell	-4,100	Closed	-$970K	–	4408
2014 Q3	$970K	Buy	+4,100	New	+$1.05M	﹤0.01%	3355

JP Morgan Chase's ICPT Position: Q4 2023 in Review

JP Morgan Chase sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 289,771 shares — an estimated $5.37M sold.

JP Morgan Chase first reported a position in ICPT in Q2 2013 and held it in 40 quarters. The position peaked at $189M in Q4 2019. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.

JP Morgan Chase reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
JP Morgan Chase sold 289,771 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $5.37M.
JP Morgan Chase first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2013 and held it in 40 quarters.
JP Morgan Chase's Intercept Pharmaceuticals, Inc. position peaked at $189M in Q4 2019.
0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.

Based on JP Morgan Chase's 13F filing for Q4 2023, filed 12 Feb 2024.